HERZLIYA, Israel and CALGARY, AB, Nov. 27, 2025 /CNW/ — Innocan Pharma Corporation (CSE:INNO) (FSE: IP4) (OTC:INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its financial consolidated results for the nine months ended September 30, 2025 and provide a Company update.
Iris Bincovich, CEO of Innocan, said: “As published in the esteemed Journal of Precision Nanomedicine and Frontiers in Pharmacology journal, Innocan continues to advance the pre-clinical development of LPT-CBD to support compliance with both the FDA and the CVM requirements for development.
Preliminary pharmacokinetic and safety evaluations of LPT-CBD in minipigs, provide encouraging support for Innocan’s regulatory strategy to advance LPT-CBD IND-enabling studies in alignment with FDA standards.
In addition, meaningful pre-clinical data provides clinically translatable insights supporting the intended chronic use of LPT-CBD for pain management.
Despite an unstable US market, the Consumer Wellness business continued to demonstrate resilience and solid profitability, together with continued strengthening of the Company’s balance sheet.
We are progressing towards the next important milestone of a U.S. public offering.
FISCAL 2025 NINE MONTHS SELECT FINANCIAL RESULTS (unaudited)
(US$ in millions)
Nine Months Ended
30 September
Percentage
Change
2025
2024
Revenues
21.624
24.036
(10.0 %)
Gross Profit
19.501
21.778
(10.5 %)
Gross Margin
90.2 %
90.6 %
Operating Profit (Loss)
(0.333)